Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea: A multicentre cohort analysis

Seon Sook Han, Su Jin Lee, Jae Joon Yim, Jin Hwa Song, Eun Hye Lee, Young Ae Kang

Research output: Contribution to journalArticle

Abstract

Objective Healthcare workers (HCWs) are one of the target groups for systematic testing and treatment of latent tuberculosis infection (LTBI) in a setting of low TB incidence. We performed this study to describe the testing of HCWs for LTBI and analyse the acceptance and completion of treatment of LTBI. Methods This retrospective cohort study was conducted in four university-affiliated hospitals between January 1 and December 31, 2018. HCWs with positive interferon-gamma release assay (IGRA) during LTBI screening were analysed. We assessed the acceptance and completion of LTBI treatment. Results Overall, 893 HCWs were IGRA positive. Among them, 609 HCWs visited the clinic for evaluation of LTBI. Of 609 HCWs who were evaluated, 302 (49.6%) were offered treatment for LTBI. The proportion of acceptance for treatment was 64.5% (195 of 302 HCWs). The treatment course was completed by 143 of 195 HCWs (73.3%). Three months of isoniazid and rifampin (3HR) was used in 137 HCWs (70.3%) and 4 months of rifampin (4R) in 58 (29.7%). 72 HCWs (36.9%) experienced at least one adverse drug events, but there was no different characteristics between completer and non-completer. Conclusion The acceptance and completion of LTBI treatment were unsatisfactory. Subjective perspective regarding obstacles to treatment of LTBI needs to be explored to increase compliance to LTBI treatment.

Original languageEnglish
Article numbere0222810
JournalPloS one
Volume14
Issue number9
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Latent Tuberculosis
health care workers
Rifampin
Korea
tuberculosis
Interferon-gamma
Korean Peninsula
Assays
Cohort Studies
Delivery of Health Care
Isoniazid
Testing
infection
Screening
Interferon-gamma Release Tests
rifampicin
Pharmaceutical Preparations
interferon-gamma
isoniazid
assays

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Han, Seon Sook ; Lee, Su Jin ; Yim, Jae Joon ; Song, Jin Hwa ; Lee, Eun Hye ; Kang, Young Ae. / Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea : A multicentre cohort analysis. In: PloS one. 2019 ; Vol. 14, No. 9.
@article{11e005f3d16244ed8e7f5f1012366a8e,
title = "Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea: A multicentre cohort analysis",
abstract = "Objective Healthcare workers (HCWs) are one of the target groups for systematic testing and treatment of latent tuberculosis infection (LTBI) in a setting of low TB incidence. We performed this study to describe the testing of HCWs for LTBI and analyse the acceptance and completion of treatment of LTBI. Methods This retrospective cohort study was conducted in four university-affiliated hospitals between January 1 and December 31, 2018. HCWs with positive interferon-gamma release assay (IGRA) during LTBI screening were analysed. We assessed the acceptance and completion of LTBI treatment. Results Overall, 893 HCWs were IGRA positive. Among them, 609 HCWs visited the clinic for evaluation of LTBI. Of 609 HCWs who were evaluated, 302 (49.6{\%}) were offered treatment for LTBI. The proportion of acceptance for treatment was 64.5{\%} (195 of 302 HCWs). The treatment course was completed by 143 of 195 HCWs (73.3{\%}). Three months of isoniazid and rifampin (3HR) was used in 137 HCWs (70.3{\%}) and 4 months of rifampin (4R) in 58 (29.7{\%}). 72 HCWs (36.9{\%}) experienced at least one adverse drug events, but there was no different characteristics between completer and non-completer. Conclusion The acceptance and completion of LTBI treatment were unsatisfactory. Subjective perspective regarding obstacles to treatment of LTBI needs to be explored to increase compliance to LTBI treatment.",
author = "Han, {Seon Sook} and Lee, {Su Jin} and Yim, {Jae Joon} and Song, {Jin Hwa} and Lee, {Eun Hye} and Kang, {Young Ae}",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0222810",
language = "English",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea : A multicentre cohort analysis. / Han, Seon Sook; Lee, Su Jin; Yim, Jae Joon; Song, Jin Hwa; Lee, Eun Hye; Kang, Young Ae.

In: PloS one, Vol. 14, No. 9, e0222810, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea

T2 - A multicentre cohort analysis

AU - Han, Seon Sook

AU - Lee, Su Jin

AU - Yim, Jae Joon

AU - Song, Jin Hwa

AU - Lee, Eun Hye

AU - Kang, Young Ae

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective Healthcare workers (HCWs) are one of the target groups for systematic testing and treatment of latent tuberculosis infection (LTBI) in a setting of low TB incidence. We performed this study to describe the testing of HCWs for LTBI and analyse the acceptance and completion of treatment of LTBI. Methods This retrospective cohort study was conducted in four university-affiliated hospitals between January 1 and December 31, 2018. HCWs with positive interferon-gamma release assay (IGRA) during LTBI screening were analysed. We assessed the acceptance and completion of LTBI treatment. Results Overall, 893 HCWs were IGRA positive. Among them, 609 HCWs visited the clinic for evaluation of LTBI. Of 609 HCWs who were evaluated, 302 (49.6%) were offered treatment for LTBI. The proportion of acceptance for treatment was 64.5% (195 of 302 HCWs). The treatment course was completed by 143 of 195 HCWs (73.3%). Three months of isoniazid and rifampin (3HR) was used in 137 HCWs (70.3%) and 4 months of rifampin (4R) in 58 (29.7%). 72 HCWs (36.9%) experienced at least one adverse drug events, but there was no different characteristics between completer and non-completer. Conclusion The acceptance and completion of LTBI treatment were unsatisfactory. Subjective perspective regarding obstacles to treatment of LTBI needs to be explored to increase compliance to LTBI treatment.

AB - Objective Healthcare workers (HCWs) are one of the target groups for systematic testing and treatment of latent tuberculosis infection (LTBI) in a setting of low TB incidence. We performed this study to describe the testing of HCWs for LTBI and analyse the acceptance and completion of treatment of LTBI. Methods This retrospective cohort study was conducted in four university-affiliated hospitals between January 1 and December 31, 2018. HCWs with positive interferon-gamma release assay (IGRA) during LTBI screening were analysed. We assessed the acceptance and completion of LTBI treatment. Results Overall, 893 HCWs were IGRA positive. Among them, 609 HCWs visited the clinic for evaluation of LTBI. Of 609 HCWs who were evaluated, 302 (49.6%) were offered treatment for LTBI. The proportion of acceptance for treatment was 64.5% (195 of 302 HCWs). The treatment course was completed by 143 of 195 HCWs (73.3%). Three months of isoniazid and rifampin (3HR) was used in 137 HCWs (70.3%) and 4 months of rifampin (4R) in 58 (29.7%). 72 HCWs (36.9%) experienced at least one adverse drug events, but there was no different characteristics between completer and non-completer. Conclusion The acceptance and completion of LTBI treatment were unsatisfactory. Subjective perspective regarding obstacles to treatment of LTBI needs to be explored to increase compliance to LTBI treatment.

UR - http://www.scopus.com/inward/record.url?scp=85072372406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072372406&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0222810

DO - 10.1371/journal.pone.0222810

M3 - Article

C2 - 31536577

AN - SCOPUS:85072372406

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e0222810

ER -